RESUMEN
Aminolevulinic acid photodynamic therapy (ALA-PDT) is an effective and noninvasive therapy for superficial basal cell carcinoma (BCC) and Bowen's disease. It also may have a role in the treatment of nodular BCC and other cutaneous malignancies, including localized cutaneous lymphomas. ALA-PDT offers multiple advantages over traditional treatments, including little to no scarring, excellent cosmetic results, and the ability to treat multiple lesions simultaneously. It is not an effective therapy for aggressive subtypes of BCC or for invasive squamous cell carcinoma. Finally, ALA-PDT may be a useful way to prevent new skin cancers in certain high-risk patients.
Asunto(s)
Ácido Aminolevulínico/uso terapéutico , Fotoquimioterapia , Fármacos Fotosensibilizantes/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológico , Ácido Aminolevulínico/efectos adversos , Enfermedad de Bowen/tratamiento farmacológico , Carcinoma Basocelular/tratamiento farmacológico , Carcinoma de Células Escamosas/tratamiento farmacológico , Humanos , Fotoquimioterapia/efectos adversosAsunto(s)
Antineoplásicos/efectos adversos , Erupciones por Medicamentos/etiología , Livedo Reticularis/inducido químicamente , Púrpura/inducido químicamente , Quinazolinas/efectos adversos , Anciano , Erupciones por Medicamentos/patología , Gefitinib , Humanos , Livedo Reticularis/patología , Masculino , Neoplasias de la Próstata/tratamiento farmacológico , Púrpura/patología , Piel/patologíaAsunto(s)
Antimetabolitos Antineoplásicos/administración & dosificación , Linfoma Anaplásico de Células Grandes/tratamiento farmacológico , Metotrexato/administración & dosificación , Antimetabolitos Antineoplásicos/uso terapéutico , Femenino , Humanos , Inyecciones Intralesiones , Metotrexato/uso terapéutico , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
We present a case of a 40-year-old woman with a history of a wide local excision for a melanoma and subsequent postoperative soft tissue loss who was successfully treated with injectable poly-L-lactic acid (Sculptra). After only one treatment with the filler agent, the treated area showed significant volume enhancement and improved cosmesis 10 months postinjection. We propose a possible role for injectable poly-L-lactic acid in improving the appearance of postoperative volume loss.
Asunto(s)
Ácido Láctico/uso terapéutico , Polímeros/uso terapéutico , Cuidados Posoperatorios/métodos , Complicaciones Posoperatorias/tratamiento farmacológico , Traumatismos de los Tejidos Blandos/tratamiento farmacológico , Adulto , Técnicas Cosméticas , Femenino , Humanos , Inyecciones , Ácido Láctico/administración & dosificación , Melanoma/cirugía , Poliésteres , Polímeros/administración & dosificación , Resultado del TratamientoRESUMEN
Antiphospholipid syndrome (APS) is a hypercoagulable disorder that results in vascular thrombosis. The symptoms are numerous and depend on the size and location of the vessels involved. Patients with this condition can have significant morbidity and occasionally mortality. It is important for dermatologists to be knowledgeable about APS because a large percentage of patients with this condition will present with dermatologic manifestations. If diagnosed and treated early, patients can be spared the consequences of this serious disease.
Asunto(s)
Síndrome Antifosfolípido/fisiopatología , Púrpura/inmunología , Enfermedades Cutáneas Vasculares/inmunología , Adulto , Anticuerpos Anticardiolipina/sangre , Síndrome Antifosfolípido/complicaciones , Síndrome Antifosfolípido/diagnóstico , Biopsia con Aguja , Histocitoquímica , Humanos , Masculino , Enfermedades Cutáneas Vasculares/diagnóstico , Enfermedades Cutáneas Vasculares/patologíaRESUMEN
Generalized essential telangiectasia (GET) is a well-established but seldom reported disorder. Patients with this condition develop widespread telangiectasias for no known reason. Although the condition can be cosmetically and psychologically devastating, it fortunately is not associated with other diseases or complications. Treatment can be difficult and expensive, but the therapeutic benefit of providing patients with a name and prognosis for their disease cannot be overemphasized.